"I'll never forget the day I received my diagnosis - it was as if my whole world came crashing down. I was 45, healthy, and active, with no family history of cancer. But there it was: Multiple Myeloma.
"At first, I felt overwhelmed by the sheer amount of information and treatment options. But I was determined to fight. I started with chemotherapy and stem cell transplantation. The journey was grueling, with countless hospital visits, painful procedures, and debilitating side effects.
"Despite the challenges, I remained optimistic, focusing on the little victories along the way. I learned to appreciate the beauty of life's simple moments - a stunning sunset, a warm cup of coffee, or a good book.
"Throughout my treatment, I was fortunate to have an incredible support system. My family and friends stood by me, offering love, encouragement, and practical help. My medical team was also exceptional, providing expert care and guidance every step of the way.
"It's been five years since my diagnosis, and I'm thrilled to say that I'm in remission. While multiple myeloma will always be a part of my life, I refuse to let it define me. Instead, I've chosen to use my experience to help others, raising awareness and supporting research for this rare and complex disease.
"My journey with multiple myeloma has taught me the value of resilience, gratitude, and hope. I've learned to cherish every moment, to appreciate the beauty of life, and to never give up, no matter what challenges come my way."

Your Feed
Filter by
See content from
Playlist: Classes of Drugs
What are some newer drug classes being studied to treat follicular lymphoma?
Video details & playlist
Playlist: ASH 2024
Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024
Video details & playlist
Playlist: ASH 2024
The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024
Video details & playlist
Playlist: ASH 2024
Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
Video details & playlist
Playlist: ASH 2024
Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Quality of Life Dispairities for Patients with MDS | Somedeb Ball, MBBS | #ASH24
Video details & playlist






